4.7 Article

A role for IL-27p28 as an antagonist of gp130-mediated signaling

期刊

NATURE IMMUNOLOGY
卷 11, 期 12, 页码 1119-U118

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ni.1957

关键词

-

资金

  1. US National Institutes for Health [AI-042334, AI-054488, 1-T32-AI-055428, 2-T32-AI-007532-11]
  2. Abramson Cancer Center (Center for Digestive Diseases)
  3. State of Pennsylvania
  4. Deutsche Forschungsgemeinschaft (Bonn, Germany) [SFB415, B5, SFB415, B7]
  5. Cluster of Excellence 'Inflammation at Interfaces'
  6. Marie Lowe Cancer Center of the University of Pennsylvania
  7. Versus Arthritis [18286] Funding Source: researchfish

向作者/读者索取更多资源

The heterodimeric cytokine interleukin 27 (IL-27) signals through the IL-27R alpha subunit of its receptor, combined with gp130, a common receptor chain used by several cytokines, including IL-6. Notably, the IL-27 subunits p28 (IL-27p28) and EBI3 are not always expressed together, which suggests that they may have unique functions. Here we show that IL-27p28, independently of EBI3, antagonized cytokine signaling through gp130 and IL-6-mediated production of IL-17 and IL-10. Similarly, the ability to generate antibody responses was dependent on the activity of gp130-signaling cytokines. Mice transgenic for expression of IL-27p28 showed a substantial defect in the formation of germinal centers and antibody production. Thus, IL-27p28, as a natural antagonist of gp130-mediated signaling, may be useful as a therapeutic for managing inflammation mediated by cytokines that signal through gp130.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据